The current standard treatment for resectable tumours in clinical stages II and III is neoadjuvant radio(chemo)therapy. Improved radiation techniques and chemotherapy (CT) with continuous infusion of 5-FU during adjuvant radiotherapy (RT) has led to an additional improvement of adjuvant therapeutic results. The efficacy of new cytostatic drugs and antibodies is presently being clinically tested for perioperative therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF03365075 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!